The evolving role of natural products in drug discovery

By F. Koehn, G. Carter. Nature reviews. Drug discovery, 2005

2,502 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/a63e109cbfa78b10fdae41197525330e4be4e358

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Molecular Biology

In Pharmacology

Citations in the corpus

The exploration of macrocycles for drug discovery — an underexploited structural class (2008, background): “Several macrocyclic drugs can be described as having a 'modulator' domain, a sub-region in which the details of molecular structure can be altered without affecting target affinity, but which completes the macrocyclic architecture and positions functional groups for binding (for example the 'spacer'”
Drug development from marine natural products (2009, background): “This has partly been driven by new developments in analytical technology, spectroscopy and high-throughput screenin”
Drug discovery from medicinal plants. (2005, background): “As such, many pharmaceutical companies have eliminated or scaled down their natural product research (Butler, 2004; Koehn and Carter, 2005).”
Natural products and drug discovery (2009, background): “Moreover, natural products have also been an invaluable source of inspiration for organic chemists to synthesize novel drug candidates (Beghyn et al, 2008; Hunter, 2008; Koehn & Carter, 2005).”
Natural products as leads to anticancer drugs (2007, background): “pounds with pharmacological activity and extraordinary therapeutic possibilities [6–11].”
Enrichment method for the isolation of bioactive actinomycetes from mangrove sediments of Andaman Islands, India (2011, background): “Although, considerable progress is being made within the fields of chemical synthesis and engineered biosynthesis of antibacterial compounds, nature still remains the richest and the most versatile source for new antibiotics (Kpehn and Carter, 2005; Baltz, 2006; Pelaez, 2006).”
Developing a new resource for drug discovery: marine actinomycete bacteria (2006, background): “However, drug discovery strategies changed in the 1990s as techniques in combinatorial chemistry, high-throughput screening, and computer-assisted design of small-molecule ligands created alternatives to traditional drug discovery paradigm”
Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, methodology): “…biological actions due to binding affinities for specific proteins relevant for their biological functions, possess superior chemical diversity and complexity developed during biosynthesis (Clardy and Walsh, 2004; Koehn and Carter, 2005), and often have more advantageous ADME/T properties.”
Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. (2011, background): “Besides known ligand molecules, ligand-based methods may also include natural products or substrate analogues that interact with the target molecule yielding the desired pharmacological effect [23-27].”
Natural product discovery: past, present, and future (2016, background): “We cannot accurately state the number of NCEs discovered during this period, but the number of patents filed world-wide exceeded 1300 [70].”